Neumora Therapeutics' (NMRA) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Neumora Therapeutics' stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, following a trend of mixed evaluations from other analysts.
• The company reported an EPS of ($0.33), surpassing analyst estimates of ($0.38), while research analysts forecast an EPS of -1.61 for the current year.
• Recent investment movements indicate significant increases in stakes by institutional investors, including a 793.5% increase by California State Teachers Retirement System in the last quarter.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report)'s stock had its "sell (d-)" rating restated by investment analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

NMRA has been the subject of a number of other research reports. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from a "neutral" rating to an "underweight" rating in a research report on Tuesday, September 16th. Mizuho lifted their price target on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $7.14.

Neumora Therapeutics Stock Up 4.3%

Shares of NASDAQ NMRA opened at $1.94 on Wednesday. The company has a 50 day simple moving average of $1.68 and a 200 day simple moving average of $1.20. The firm has a market cap of $314.18 million, a PE ratio of -1.24 and a beta of 2.92. Neumora Therapeutics has a 1 year low of $0.61 and a 1 year high of $17.19. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.54 and a quick ratio of 10.54.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.05. On average, research analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

Several large investors have recently added to or reduced their stakes in NMRA. California State Teachers Retirement System increased its holdings in Neumora Therapeutics by 793.5% in the 4th quarter. California State Teachers Retirement System now owns 54,457 shares of the company's stock worth $577,000 after acquiring an additional 48,362 shares during the last quarter. Lunate Capital Ltd purchased a new stake in Neumora Therapeutics in the 1st quarter worth about $2,124,000. Cerity Partners LLC increased its holdings in Neumora Therapeutics by 24.0% in the 1st quarter. Cerity Partners LLC now owns 302,505 shares of the company's stock worth $303,000 after acquiring an additional 58,597 shares during the last quarter. CWM LLC increased its holdings in Neumora Therapeutics by 7,124.4% in the 1st quarter. CWM LLC now owns 25,213 shares of the company's stock worth $25,000 after acquiring an additional 24,864 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in Neumora Therapeutics in the 1st quarter worth about $285,000. Hedge funds and other institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.